Anshul Maheshwari Sells 5,229 Shares of SiBone (NASDAQ:SIBN) Stock

SiBone (NASDAQ:SIBN) CFO Anshul Maheshwari sold 5,229 shares of the stock in a transaction that occurred on Friday, January 2nd. The stock was sold at an average price of $19.64, for a total value of $102,697.56. Following the sale, the chief financial officer owned 180,002 shares in the company, valued at approximately $3,535,239.28. This trade represents a 2.82% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website.

Anshul Maheshwari also recently made the following trade(s):

• On Thursday, December 18th, Anshul Maheshwari sold 18,542 shares of SiBone stock. The stock was sold at an average price of $20.15, for a total value of $373,621.30.
• On Tuesday, November 25th, Anshul Maheshwari sold 100 shares of SiBone stock. The stock was sold at an average price of $20.00, for a total value of $2,000.00.
• On Friday, November 21st, Anshul Maheshwari sold 1,200 shares of SiBone stock. The shares were sold at an average price of $20.01, for a total value of $24,012.00.
• On Monday, November 17th, Anshul Maheshwari sold 3,460 shares of SiBone stock. The shares were sold at an average price of $17.43, for a total value of $60,307.80.
• On Tuesday, November 11th, Anshul Maheshwari sold 2,601 shares of SiBone stock. The stock was sold at an average price of $18.33, for a total transaction of $47,676.33.

SiBone Trading Up 4.9%

SIBN opened at $21.40 on Thursday. The company has a current ratio of 7.97, a quick ratio of 6.62 and a debt-to-equity ratio of 0.21. The stock has a market capitalization of $928.55 million, a PE ratio of -41.96 and a beta of 0.69. SiBone has a 1-year low of $12.49 and a 1-year high of $21.49. The firm has a 50-day moving average price of $18.71 and a two-hundred day moving average price of $17.07.

SiBone (NASDAQ:SIBN) last posted its quarterly earnings data on Monday, November 10th. The company reported ($0.11) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.16) by $0.05. SiBone had a negative return on equity of 12.86% and a negative net margin of 11.24%.The firm had revenue of $48.66 million for the quarter, compared to the consensus estimate of $46.67 million. As a group, equities analysts anticipate that SiBone will post -0.78 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

SIBN has been the topic of several recent research reports. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of SiBone in a research note on Monday, December 29th. Truist Financial increased their price objective on shares of SiBone from $21.00 to $23.00 and gave the company a “buy” rating in a report on Thursday, December 18th. Morgan Stanley raised their price objective on shares of SiBone from $20.00 to $23.00 and gave the company an “overweight” rating in a research note on Tuesday, December 2nd. Needham & Company LLC upped their target price on shares of SiBone from $24.00 to $27.00 and gave the company a “buy” rating in a research report on Tuesday, December 16th. Finally, Canaccord Genuity Group increased their price target on SiBone from $26.00 to $27.00 and gave the company a “buy” rating in a research note on Wednesday, December 17th. Five research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company’s stock. According to MarketBeat.com, SiBone has a consensus rating of “Moderate Buy” and an average price target of $25.00.

Institutional Investors Weigh In On SiBone

Hedge funds and other institutional investors have recently made changes to their positions in the stock. State of Alaska Department of Revenue bought a new stake in shares of SiBone during the 3rd quarter worth approximately $39,000. State of Wyoming bought a new stake in SiBone during the second quarter worth about $55,000. Canada Pension Plan Investment Board acquired a new stake in shares of SiBone during the 2nd quarter worth approximately $68,000. Quarry LP increased its stake in shares of SiBone by 862.6% in the 3rd quarter. Quarry LP now owns 4,861 shares of the company’s stock valued at $72,000 after purchasing an additional 4,356 shares during the last quarter. Finally, Tower Research Capital LLC TRC raised its stake in SiBone by 198.8% during the second quarter. Tower Research Capital LLC TRC now owns 4,897 shares of the company’s stock worth $92,000 after acquiring an additional 3,258 shares in the last quarter. 98.11% of the stock is currently owned by institutional investors and hedge funds.

SiBone Company Profile

Si-BONE, Inc is a commercial‐stage medical device company focused on the design, development and commercialization of implant systems to treat degenerative conditions of the sacroiliac (SI) joint. Its flagship product, the iFuse Implant System, consists of triangular titanium implants that are inserted via a minimally invasive surgical procedure to stabilize the SI joint and alleviate chronic lower back and buttock pain.

FDA‐cleared in 2012, the iFuse portfolio has expanded to include the iFuse-3D and iFuse-3Di devices, which feature a porous, 3D-printed surface to promote bone ongrowth and biological fixation.